Renamed Lipoxen turns to Russia to derisk biotech development
This article was originally published in Scrip
Executive Summary
"We want to derisk our approach to biotech drug discovery." So says Scott Maguire, CEO of the UK firm formerly known as Lipoxen. The company has just undergone a complicated series of transactions and manoeuvres aimed at taking advantage of the Russian government's interest in investing in biotech. The company has established a business model that enables it to launch its products early into Russia or India before deciding which ones to develop further for North American and European markets.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.